Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Double E who wrote (1383)	7/28/1998 10:12:00 AM
From: Joe	Respond to of 4140

This release is exactly what the doctor ordered. Companies can indeed go way beyond this type of press release prior to FDA approval. Notable examples were BEAM prior to approval as well as VISX to a lesser extent. What they cannot do is appear to be marketing the product. This was a good a press release. It tells me that SNRS is acting in a manner that is in the best interest of the shareholders. After receiving the ophthalmic panel's recommendation for approval of hyperopic PRK & LASIK, it is announced that a leading ophthalmologist, possibly a Visx customer, and his wife choose to be treated with Sunrise LTK! While this was not a news event, this was and is great reassurance to shareholders. It may not directly affect stock price, but it directly affects shareholder's confidence. I don't know if Omnicom put this together or not, but it is a clear signal that Sunrise intends to become more aggressive in keeping the shareholders and the public informed. I think they are probably doing ok with ophthalmologists already, but there is probably room for improvement. Regards, Joe